Home Contact COMPANY Forendo Pharma is a drug discovery and development company with core competence in tissue specific regulation of sex hormone effects. Its two first-in-class product candidates are progressing to offer significant therapeutic benefits in men´s and women´s health FISPEMIFENE Fispemifene is the first selective estrogen receptor modulator designed only for men. It will be developed for treatment of symptoms of low testosterone. In phase II clinical studies in men with secondary hypogonadism, fispemifene has effectively normalized the low testosterone levels. HSD 17HSD1-inhibitor is progressing into clinical development with a focus on endometriosis. The potent and selective lead compounds have demonstrated in vivo proof of efficacy in disease model of endometriosis. This “first-in-man” mechanism offers potentially multiple benefits over the current endometriosis therapies. Press release June 25, 2013 • Pasi Koskimies Forendo Pharma: a new drug development company started in Turku with focus on endometriosis and male low testosterone Turku June 25th, 2013. Forendo Pharma OY has announced today that it has closed its first investment round with the leading Nordic start-up investors Karolinska Development AB, Novo Seeds and Finnvera. The tranched funding commitments together with funding from Tekes will reach 10 million euros. Forendo Pharma has acquired from Hormos Medical the drug development programs for endometriosis and male low testosterone. Read the full article… Copyright © 2013 Forendo Pharma. All rights reserved.